Interestingly, in this study, it was shown that in some patients that were positive for EGFR mutations in the primary tissue, a lack of EGFR mutations in their plasma was observed and this was associated with better PFS; this could be possibly explained as a result of lower tumor burden that was shed in the plasma [154]. The gene discussed is EGFR; the disease is neoplasm.